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Abstract
Ca2+/calmodulin-dependent protein kinase II (CaMKII) has been identified as an
important modulator in controlling electrical activity in neurons and the heart; however, a
role for CaMKII in pancreatic alpha cell signaling has not been previously reported.
Upon activation by calcium/calmodulin, CaMKII phosphorylates proteins involved in
intracellular Ca2+ homeostasis by inducing downstream effects such as an increase in
AMPA-receptor single channel conductance, potentiation of L-type voltage dependent
Ca2+ channels, and enhanced surface expression of inhibitory GABAA-receptors. In the
pancreas, an increase in intracellular calcium drives secretion of glucagon from alpha
cells within the Islets of Langerhans. α-cells contain many of the known targets of
CaMKII described in neurons, including AMPA/GluR1 receptors, L-type VGCC and
GABAA-receptors. CaMKII may also regulate other aspects of glucagon secretion, aside
from calcium homeostasis, such as vesicle trafficking, exocytosis, and cytoskeleton
dynamics. Based on the expression of CaMKII targets and the requirement of Ca2+ influx
for hormone secretion, we explored which CaMKII genes, if any, are found in α-cells,
and are involved in the regulation of α-cell signaling and glucagon release.
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Introduction
Glucose regulation in the islet
The majority of the pancreas is composed of exocrine glands responsible for
secreting pancreatic fluid into the intestine after/during digestion. Throughout the
pancreas are clusters of endocrine cells called Islets of Langerhans. An Islet of
Langerhans contains four types of cells, each with its own important endocrine function
in glucose homeostasis: α-, ß-, δ-, and PP cells. ß-cells, which account for 70-85% of the
islet, are responsible for secreting insulin in response to a rise in circulating blood
glucose levels, referred to as hyperglycemic conditions. Insulin lowers blood glucose by
stimulating muscle fibers to take up glucose, metabolize amino acids from the blood, and
stimulate the liver to take up glucose and prevent the breakdown of glycogen. α-cells,
which account for 10-15% of total islet cells, secrete glucagon in response to lowered
blood glucose levels, also called hypoglycemic conditions. Glucagon increases blood
glucose by promoting hepatic glucose output via gluconeogenesis (conversion of
glycogen into glucose) and glycogenolysis (breakdown of fat and protein into glucose).
The remaining two cell types within the islet, δ- and PP cells, are responsible for
secreting the hormone somatostatin. These cell types account for 3-10% of total islet
cells. Rodent islets are arranged with the ß-cells concentrated in the core of the islet,
surrounded by α- and δ-cells in the mantle (Gromada et al., 2007).
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Cells within the islet form a bi-hormonal system. If one cell type becomes
dysfunctional, glucose homeostasis is not maintained resulting in uncontrolled blood
glucose levels. Type 1 diabetes, known as insulin-dependent diabetes mellitus or IDDM,
results from the loss of the ß-cell population within the islet. Destruction results from a
cell-mediated autoimmune attack on ß-cells, preventing insulin production and secretion.
Under this condition, α-cells compose approximately 75% of the total cell mass within
the islet; however, the ratio of α-cells to PP- and δ-cells remains the same (Gromada et
al., 2007). Also referred to as juvenile diabetes, onset of type 1 diabetes usually occurs in
childhood. Type 2 diabetes, also known as non insulin-dependent diabetes mellitus
(NIDDM), is a multimodal disease, with many possible factors leading to insulin
resistance. This could derive from inadequate levels of glucose transporters within the
plasma membrane of skeletal muscles, problems in sensing and transporting insulin,
increasing age, or genetic factors, all of which result in insulin resistance. Type 1 and
type 2 diabetes have also been associated with elevated levels of glucagon secretion,
which would exacerbate chronic hyperglycemia caused by insulin deficiency (Marchand
et al., 2010). Identifying regulators of glucagon secretion is critical in establishing
treatment options for patients with diabetes.

Physiological regulation of endocrine pancreatic cells
The physiological regulation of insulin secretion from ß-cells has been well
studied (reviewed by Minami et al., 2011, Rorsman et al., 1996, 2012, 2013). Research
has shown that exocytosis of insulin from vesicles requires an increase in intracellular
calcium via voltage gated calcium channels (VGCC). The opening of these calcium
2

channels is regulated by ATP-sensitive potassium channels (KATP). At low plasma
glucose levels, KATP channels open and potassium is able to leave the cell, maintaining a
hyperpolarized membrane potential of –60 mV. ß-cells remain inactive under these
conditions. Insulin is secreted from ß-cells in response to a sensing mechanism triggered
by an increase in extracellular glucose from resting, or basal levels. As opposed to
receptor binding, glucose needs to be actively transported into the cytoplasm and
metabolized to stimulate exocytosis via glucose transporters (reviewed in Hiriart et al.,
2008). As shown in Figure 1, when blood glucose increases, glucose enters the cell and
is metabolized, generating ATP. As more ATP accumulates within the cell, the
ATP/ADP ratio level increases causing the KATP channels to close. Potassium is no
longer able to leave the cell though these channels, resulting in a membrane
depolarization. This depolarization initiates electrical activity, calcium influx, and
insulin secretion (Ashcroft et al., 2012).
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When blood glucose levels drop, the counter-regulatory response is critical to
prevent or quickly correct hypoglycemia. Similar to ß-cells, an increase in internal Ca2+
through VGCCs is required for glucagon secretion from α-cells. The factors influencing
the increased [Ca2+]i within the α-cell are poorly understood. Three mechanisms have
been proposed to mediate the α-cell response to hypoglycemia. The first mechanism
involves relief from inhibitory paracrine/endocrine influences by neighboring ß- and δcells (discussed later). The second mediator is the autonomic input from sympathetic
nerves, parasympathetic nerves, and circulating epinephrine (Gromada et al., 2007). The
autonomic inputs are controlled by a glucose sensing mechanism, similar to ß-cells.
Sympathetic and parasympathetic nerves follow arterioles into the islet, and release
neurotransmitters (norepinephrine, and acetylcholine (ACh)) near islet alpha and beta
cells (Taborsky, 2010). Activation of these autonomic inputs increases glucagon
secretion. The third mechanism is a direct effect of hypoglycemia to stimulate α-cell
secretion, though this mechanism is still controversial. In vitro data suggest low glucose
increases glucagon secretion from isolated perfused pancreas, but results from single
dissociated alpha cells have been controversial (Taborsky et al., 2010, Gramada et al.,
2007).
Both α- and ß-cells possess KATP channels, but unlike ß-cell physiology,
increased glucose does not increase glucagon secretion from α-cells in intact islets. It is
important to note, however, that when alpha cells are isolated from beta cells, increased
glucose does stimulate secretion. This suggests downstream machinery within the α-cells
5

is responsible for controlling electrical activity and glucagon secretion. α-cells express
voltage-dependent Na+ channels that, when inactivated, contribute to the termination of
action potential firing, thus inhibiting excitability. In contrast to ß-cells, which mainly
rely on L-type calcium channels for secretion, α-cells express N-type calcium channels
important for glucagon release in response to hypoglycemia (MacDonald et al., 2005).
Glucagon secretion is stimulated within a window of intermediate α-cell KATP activity.
When glucose levels are neither elevated nor low, this intermediate activity supports
regenerative electrical responses through the activation of voltage-dependent Na+ and Ntype Ca2+ channels. The L-type channels are important for Ca2+ current within the α-cell
due to agents increasing cAMP activity (MacDonald et al., 2005).
It is thought that glucose acts directly on murine α-cells to suppress oscillations in
intracellular free Ca2+ concentration in the absence of paracrine influences from ß-cells
(Marchand et al., 2010). It has been proposed that when glucose levels are elevated,
intracellular ATP concentrations increase and cause partial closure of KATP channels,
resulting in the inactivation of N-type Ca2+ channels and voltage-gated Na+ channels,
suppression of electrical activity, and Ca2+ influx through L-type Ca2+ channels through
the activation of Ca2+ uptake by the ER, the consequent inactivation of a store-operated
current that results in plasma membrane hyperpolarization, and decreased Ca2+ influx
through voltage-gated Ca2+ channels (Rutter, 2009).

Paracrine signaling within the islet of Langerhans
The intracellular mechanisms underlying the suppression of glucagon secretion
are not completely understood, but two general models have been proposed. The first
6

model proposes that inhibition is caused directly by changes in blood glucose levels, as
already discussed. The second model involves paracrine inhibition from non-alpha cells
within the Islet of Langerhans (Marchand et al., 2010). It is thought that insulin secreted
from ß-cells tonically inhibits glucagon secretion from the alpha cells, and could
therefore contribute to the alpha cell response to hypoglycemia when insulin secretion is
suppressed. Molecules secreted from the ß-cells such as gamma amino butyric acid
(GABA) and zinc have also been implicated in the suppression of glucagon secretion
(Figure 2) (Taborsky et al., 2010).
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Figure 2: Paracrine effect of GABA and glutamate on α-cell glucagon secretion.
Several factors released from the beta cells suppress glucagon secretion. When blood
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GABAA receptors on the outside of the alpha cells. GABA binds to the receptor, causing
the channel to open and Cl- ions to enter the cell. This causes hyperpolarization of the
cell, and inactivation of voltage gated calcium channels. There are also factors that
increase glucagon secretion. Glutamate is co-secreted with glucagon and acts to
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The secretion of somatostatin from δ–cells is also thought to suppress glucagon
secretion from alpha cells and insulin secretion from beta cells, however, results have
been inconclusive.
Two interesting paracrine factors present in islets that affect glucagon secretion
are GABA and glutamate. GABA is a non-peptidal neurotransmitter well known for its
inhibitory effect on neuronal firing in the central nervous system (CNS). GABA is
synthesized from glutamic acid by glutamic acid decarboxylase (GAD). In neurons,
GABA is released when voltage-sensitive calcium channels open allowing GABA to
interact with ionotropic receptors increasing their chloride conductance, inducing
membrane hyperpolarization and resulting in the inhibition of exocytosis. ß-cells within
the endocrine pancreas contain high concentrations of GABA and GAD (Franklin et al.,
2004). Studies have shown that GABA secretion from ß-cells can be stimulated by high
concentrations of extracellular K+ and by treatment with various calcium ionophores and
peptides including, IBMX, a cyclic AMP-raising agent, and mastopran, a peptide that
activates G-proteins and stimulates LDVC exocytosis (Franklin et al., 2004). These
results suggest that, like insulin, GABA is released in response to an increase in cytosolic
calcium as a result of membrane depolarization.
Functional GABAaRs are expressed in α-cells. In the αTC1-6 cell line, glucagon
secretion can be inhibited by GABA in a dose-dependent manner, in low (1mM) but not
high (10mM) glucose (Gaskins et al., 1995). It has been proposed that during
hyperglycemia GABA is co-released with insulin from the ß–cells and acts on the
GABAaRs on α-cells to reduce glucagon secretion (Rorsman et al., 1989). These
9

findings suggest that GABA may act as a paracrine inhibitor of glucagon secretion under
high glucose conditions, but a clear mechanism has not been described.
It has been published that human α-cells express ionotropic glutamate receptors
(iGluRs) essential for glucagon release. Low glucose concentration within the islet results
in the release of glutamate from the α-cell. Glutamate then acts on iGluRs of the
AMPA/kainate type, resulting in membrane depolarization, opening of VGCC, an
increase in cytoplamics Ca2+, and enhanced glucagon release (Cabrera et al., 2008). This
glutamate autocrine feedback loop allows the α-cell to potentiate its own secretory
activity in response to small changes in physiological glucose levels (Cabrera et al.,
2008). There is also evidence that the large dense-core vesicles (LDCVs ) of α-cells
contain glutamate. It has been shown that that the glutamate transporters VGLUT1 and
VGLUT2 co-localize with glucagon-positive secretory granules and L-glutamate. Lglutamate is the primary excitatory neurotransmitter in the CNS, and is stored in and
released from synaptic vesicles. The co-localization of glutamate with glucagon could
suggest that intra-islet glutamate paracrine signaling activity occurs during hypoglycemia
(Franklin et al., 2004).

Regulation and pathways of CaMKII activation
An influx of internal Ca2+ is required for glucagon secretion from alpha cells to
occur, and many mechanisms have evolved that regulate Ca2+ influx. There are several
known pathways that directly regulate the ion channels responsible for generating and
regulating the Ca2+ influx signal. Identification of additional factors regulating calcium
influx is important in piecing together the steps leading to glucagon secretion within
10

these cells. Ca2+/calmodulin-dependent protein kinase II or CaMKII has been implicated
as an important modulator of electrical activity in neurons and the heart (Erickson et al.,
2011). CaMKII proteins are serine/threonine kinases that are encoded by four genes:
CaMKIIα, -ß, -δ and -γ. CaMKII is regulated by the Ca2+/calmodulin complex, which
mediates diverse physiological responses triggered by an increase in internal calcium
concentrations.
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Figure 3: Activation of CaMKII by phosphorylation. Calcium increases within the cell
through various routes, voltage gated Ca2+ channels (L-P-N-Q-type), ligand-gated Ca2+
channels, or through G-Protein coupled receptors which activate the IP3/RyR pathways.
Once Ca2+ increases within the cell it binds to CaMKII, along with calmodulin. Binding
of Ca2+/calmodulin activates the kinase which serve many various functions and
subcellular locations. CaMKII can also autophosphorylate itself allowing it to remain
active even after calmodulin has dissociated.
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CaMKII is activated by the binding of Ca2+/calmodulin, and can undergo
autophosphorylation (Skelding et al., 2009). CaMKII is regulated by multi-site
phosphorylation, which can alter enzyme activity and intracellular targeting (Figure 3).
CaMKII is implicated in many diverse cellular functions, including carbohydrate
metabolism, membrane current, neurotransmitter synthesis/release/transcription,
cytoskeletal organization, intracellular homeostasis, long-term potentiation, and neuronal
memory.
CaMKII function is mediated largely by its structure. The kinase is an oligomeric
protein composed of 12 subunits (Erickson et al., 2011). As shown in Figure 4, each
CaMKII gene has three critical domains: a C-terminal association domain, a regulatory
domain, and an N-terminal catalytic domain.
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Figure 4: Schematic Diagram of CaMKII structure. CaMKII contains three main
domains. The catalytic domain contains the ATP binding site, which is essential for its
enzyme activity. The regulatory domain contains the autoinhibitory domain as well as the
calmodulin binding site. Once Ca2+/Calmodulin binds, the conformation changes and it is
able to bind to ATP as well as to autophosphorylate itself at the T286 site. The 4 variable
regions within the association domain are the main sites for alternative splicing, creating
over 30 isoforms from the four CaMKII genes.
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The auto-inhibitory domain is located within the regulatory domain. When
inactive, the auto-inhibitory domain interacts with the catalytic domain, blocking the
binding of ATP and inhibiting kinase activity of the enzyme. CaMKII is maintained in
this inhibited (basal) state, until inhibitory restraints are relieved by binding of second
messengers (e.g. Ca2+/calmodulin) within the cell (Hudmon et al., 2002). Once active,
CaMKII has the unique ability to undergo auto-phosphorylation at Thr286, and because
of this transient elevation of intracellular calcium can give a prolonged response. There
are four main variable regions located within the association domain of CaMKII, through
which alternative splicing produces more than 30 isoforms from the four genes. To
further complicate CaMKII structural and functional analysis, different isoforms can coassemble into heteromeric holoenzymes, so it is likely that both homo-multimers and
hetero-multimers of CaMKII exist, which could explain the varied functional properties
of CaMKII (Skelding et al., 2009).

CaMKII function, and location
Expression of all four CaMKII genes have been observed in the brain. The -α and
-ß homologs are largely expressed in neuronal tissue, while -γ and -δ have been observed
in a wide variety of tissues (Erickson et al., 2011). CaMKIIα plays a critical role in
sustaining activation of CaMKII at the postsynaptic density (PSD), and is required for
hippocampal long-term potentiation (LTP) and spatial learning. CaMKIIα is thought to
be an important mediator of learning and memory, and important for maintaining Ca2+
homeostasis and reuptake, chloride transport, and T cell activation. CaMKIIß functions as
a targeting or docking module in the brain, and plays a nonenzymatic role in regulating F15

actin stabilization (Shen et al., 1998; Borgesius et al., 2011). CaMKIIδ is found in
neuronal and non-neuronal cell types, but has mostly been studied in the cardiovascular
system. CaMKIIδ has been implemented in RyR phosphorylation and nuclear targeting in
the heart (Erickson et al., 2011). CaMKIIγ is found in neuronal and non-neuronal cell
types, and has been shown to be a crucial extracellular signal-regulated kinase in
differentiated smooth muscle cells (Morgan et al., 2005). Because CaMKII is found in the
cytoplasm, the nucleus, and in different organelles, it can interact with many proteins
allowing it to function as a sensor and an effective transmitter of cellular signals (Erikson
et al., 2011).
Ca2+ influx stimulates CaMKII activity and T286 auto-phosphorylation. Once
active, CaMKII phosphorylates many of the proteins involved in intracellular Ca2+
homeostasis, including Cav1.2 channels and proteins involved in SR Ca2+ uptake and
release (RyR2). Other paracrine effects of CaMKII activation include an increase of
AMPA-receptor single channel conductance by phosphorylation of GluR1 subunits,
potentiation of L-type voltage dependent Ca2+ channels via their α- or ß-subunits, and
enhanced surface localization of inhibitory GABAA-receptors (Coultrap et al., 2011).
Glutamate-induced Ca2+ influx causes two forms of CAMKII translocation in the brain:
to post-synaptic sites and to extra-synaptic clusters (Coultrap et al., 2011). High ATP
ratios trigger T286 auto-phosphorylation, which enhances CaMKII binding to NMDA
receptors, and inhibits CaMKII aggregation. CaMKII aggregation causes a reduction in
the degree of activity that can be stimulated by Ca2+/CaM. CaMKII has been studied
primarily in neurons and cardiomyocytes, and there is a limited understanding of the role
of CaMKII in other tissues (Ozcan et al, 2012). Previous studies have suggested that
16

CaMKIIα translocates to inhibitory synapses in response to moderate NMDA-activating
stimuli that trigger GABAA-receptor insertion and enhance inhibitory transmission.
Accumulation of CaMKIIα at inhibitory synapses is prevented by the phosphatase
calcineurin (Marsden et al., 2010). This preferential targeting of CaMKIIα to
glutamatergic or GABAergic synapses provides neurons with a mechanism whereby
activity can selectively potentiate excitation or inhibition through a single kinase
mediator (Marsden et al., 2010). The phosphatases PP1 and PP2A can dephosphorylate
T286D-autophosphorylated CaMKIIα (Colbran et al., 2004).
An increase in internal calcium is required for secretion from alpha cells, but the
intracellular signaling mechanisms leading to secretion are still unclear. One potential
signaling molecule leading to secretion in alpha cells is CaMKII. Analysis of CaMKII
presence and function in alpha cells will be important to investigate in alpha cell
signaling and secretion because rodent α-cells, including the mouse αTC1-6 cell-line,
contain many CaMKII targets such as AMPA/GluR1 receptors, L-type VGCC, and
GABAA-receptors, all of which could affect many different aspects of alpha cell
signaling. In this study, I show that all four CaMKII genes are expressed in the αTC1-6
cell line, and in primary mouse islet cells. In addition I show that CaMKII is present in
the beta cell line, Β-min6, and in primary mouse beta cells.
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Materials and Methods

Cell Culture
The clonal mouse cell line α-TC1-6, (provided by Professor Donald Steiner from
the University of Chicago) grown in DMEM with glucose adjusted to 15mM and 10%
heat-inactivated FBS, supplemented with 1.0 mM Na-pyruvate, 1% penicillin, 1%
streptomycin, 100 µg/mL normocin, 3.7g/L sodium bicarbonate, and MEM non-essential
amino acids. Cells were maintained in a humidified incubator with 5% CO2 at 37°C.

αTC1-6 Immunofluorescence
ECL coated 35mM dishes, or 8 chambered slides were washed with F12-K media
and cells were allowed to attach overnight at 37°C. Samples were fixed with 4% PFA and
permeabilized in either 0.4% triton X-100 or 0.2% saponin. Primary antibodies were
added as listed in Table 1 and incubated at 37°C for 90 minutes. After washing with PBS,
corresponding secondary antibodies were added at 1:800 concentrations for 45 minutes at
37°C. Samples were washed, mounted with DAPI, coverslipped, sealed and stored at 4°C
until imaged. Images were acquired and analyzed using Slide Book software (Intelligent
Imaging Innovation, Denver, CO) comprised of a Zeiss Axiovert S 100 inverted

18

microscope equipped with a z-stepper motor, shutter filter wheels, and a Cooke Sensicam
CCD camera.

Islet dissociation and culture
Mouse pancreas was perfused with 4 mL (1,000 U ml-1) collagenase in HBSS via
the joint site of the hepatic duct and cystic duct. All procedures were approved by
University of Denver, IACUC. After removing the pancreas, it was digested in 1 mL of
collagenase for 15 minutes at 37°C. Digestion was terminated by adding ice-cold 1mM
CaCl2 in 1x HBSS. Islets were hand picked and plated on tissue culture dishes or prepped
for dissociation. Islets were dissociated in 5mL of 37°C trypsin/EDTA for 5 minutes and
spun at 2,500 rpm for 6 minutes to pellet cells. Cells were re-suspended in 37°C RPMI
medium containing 10.4mg/L glutamate, 10% FBS, 10mM HEPES, 1mM Na pyruvic
acid, 7 µl/L ß-mercaptoethanol, 1% pen/strep, and 3.7g/L sodium bicarbonate.

Islet Immunofluorescence
Islets were fixed in PBS containing 2% paraformaldehyde for 20 minutes at 4°C,
and permeabilized overnight, rocking at 4°C in PBS with 0.3% triton X-100, 5mM
sodium azide, 1% BSA and 5% donkey serum. Islets were allowed to settle to the bottom
of the tube, and solution was carefully changed to incubate islets in permeabilization
solution supplemented with primary antibodies for 24 hours at 4°C (rocking). Islets were
allowed to settle to the bottom of the tube, solution was carefully removed, and islets
were washed with PBS three times. Islets were put in permeabilization solution
19

supplemented with secondary antibodies for 24 hours at 4°C (rocking). Islets were
allowed to settle to the bottom of the tube, solution was removed, and islets were washed
with PBS three times before mounting on glass slides and imaging. Primary antibodies
were used at the concentrations listed in Appendix B and imaged using Alexa488,
Alexa555, and Alexa647 labeled secondary antibodies at 1:800 in 1% BSA. Images were
acquired using an Zeiss Axioplan2 inverted epifluorescence microscope equipped with a
Sutter Instrument Company Lamp, Applied Scientific Instrument z-stepper motor, a
Hamamatsu Digital CCD camera using a 100x oil objective, or an Olympus Fluoview
FV1000 confocal microscope equipped with a Melles Griot Laser Group Argon Laser,
and NTT Electronics Corporation Diode Laser, using a 60x oil objective lens with an
numerical aperture of 1.42.
Pancreatic Histology
Dissected pancreases were submerged in 4% PFA (in PBS) overnight at 4°C.
Tissue was dehydrated in 70% EtOH for one hour followed by 80% EtOH for 45
minutes, two 45 minute washes in 95% EtOH, followed by three 45 minute 100% EtOH
washes, two 1 hour incubations in neoclear, and finally two 1 hour paraffin washes.
Pancreases were embedded in paraffin. Once the block cooled overnight, 8-10 micron
sections were cut and floated onto slides in a 37°C water bath. Samples were rehydrated
in three 5 minute neoclear washes, followed by three 5 minute 100% EtOH washes, one 5
minute 95% EtOH wash, one 5 minute 70% EtOH wash, and rinsed in H2O, followed by
three one minute washes in PBS. Samples were blocked for one hour with 10% DS 2%
BSA in PBS. Primary antibodies were used at the concentrations listed in Appendix B in
20

permeabilization solution containing 0.25%BSA, .3% triton, 10% DS overnight at 4°C.
Samples were washed in blocking buffer, and Alexa488, Alexa555, oe Alexa647 labeled
secondary antibodies at 1:800 in 1% BSA were added in blocking buffer for one hour,
washed for three 5 minute washes with PBS, excess liquid was removed and mounting
media containing DAPI was added, and slides were coverslipped and sealed. Images were
acquired using a Zeiss Axioplan2 inverted epifluorescence microscope equipped with a
Sutter Instrument Company Lamp, Applied Scientific Instrument z-stepper motor, a
Hamamatsu Digital CCD camera using, and a 100x or 63x oil objective lens.

RNA isolation and cDNA synthesis
Ambion RNAqueous-4PCR DNA-free RNA isolation for RT-PCR kit was used to
isolate RNA from mouse tissue samples as well as from cultured cells. 10-12 volumes per
tissue mass of lysis/binding solution was used to disrupt cells or tissue. Lysate was
clarified by centrifugation for 2-3 minutes at top speed. Equal volume of 64% EtOH was
added to the lysate and mixed gently. Lysate/ethanol mixture was added to filter
cartridge, spun for 30 seconds at 10,000 RCF. Discard flowthrough/ repeat if necessary.
Add 700 ul Wash Solution #1 10,000 RCF 30 seconds – discard flow-through. Add 500
ul Wash Solution #2/3 10,000 RCF 30 seconds- discard flow-through. Add 500 ul Wash
Solution #2/3 10,000 RCF 30 seconds- discard flow-through. Spin 30 seconds at 100,000
RCF to dry filter. Put filter into new collection tube. Add 30-50 µl Elution Solution per
tube to center of filter- spin at 10,000 RCF for 1 minute. Add 10 µ l of 10x DNase Buffer
and 1 µl of DNase to each reaction. Incubate at 37°C for 20 min. Add 10 µ l of DNase
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inactivation reagent to each reaction, flick to mix, let sit for 1 min, flick, let sit for
additional minute. Centrifuge for 1 min at 10,000 RCF. RNA concentration was
determined using a NanoDrop spectrophotometer, and quality was checked using a
BioRad Experion RNA Std kit. RNA samples were stored at -80°C for long-term storage.
Invitrogen’s Superscript kit was used for first strand cDNA synthesis. 1.33 µg/µl
of RNA, was added to 1 µl 50mM oligo(dt)20, 1 µl 10mM dNTP mix, and brought up to
10 µl with DEPC water. Samples were incubated at 65°C for 5 min, then put on ice for 1
minute. To each reaction 10 µl of cDNA synthesis mix was added containing: 2ul 10x RT
buffer, 4 µl 25mM MgCl2, 2ul 0.1M DTT, 1 µl Rnase OUT, 1ul Superscript III RT (per
sample). Samples were incubated at 50°C for 50 minutes, reactions were terminated by
heating to 85°C for 5 minutes, and then chilled on ice. Samples were spun briefly, and 1
µl Rnase H was added to each sample and incubated at 37°C for 20 minutes. cDNA was
stored at -20°C until use for qRT-PCR.

Quantitative Real-Time PCR
Samples were prepared using Applied Biosystems pre-validated TaqMan Gene
Expresssion Assay Reagents and dye-labeled MGB primer probes. The min-6 cDNA
used was prepared by Theresa Lumsden on 10/10/07. Samples were loaded on a 96-well
plate and amplified with the Q5 Multicolor Real-Time PCR detection system iCycler,
using iQ5 software (1 cycle of 95°C for 3:00 minutes, followed by 40 cycles of 95°C for
0:10 seconds, and 60°C for 0:30 seconds). Bio-RAD iQ Supermix was made for four 25
µl reactions: 90 µl 0.2x SuperMix, 4.5 µl primer, up to 5 ug cDNA and DEPC water to
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bring volume to 156 µl. Well factor was collected for each sample. Samples were run in
quadruplicate. GAPDH was used as a control/reference gene for each cDNA sample
tested. A no template control (NTC) was run, as well as a negative cDNA control for
every plate. Samples loaded with 1x loading dye (NEB) were separated by agarose gel
(2%) electrophoresis (120 V, 30 min) and visualized using EtBr using a BioRad Gel Doc
system.

Western Analysis
Novex NuPage 4-12% Bis-Tris gels (1.0mm x 15 well) and corresponding
reagents were used to separate proteins. Gels were run at a constant amperage of 25 mA
for 10 minutes, followed by 40mA for 45 minutes. BioRad Immuno-Blot 0.45 um pore
size, LF PVDF membranes and 7.0 x 8.5 cm filter paper for fluorescent western blotting
applications were used. After protein separation gels were equilibrated in cold Towbin
buffer (25mM Tris, 192mM glycine, 20%methanol, pH 8.3) for 15 minutes. Before
transfer the membrane was soaked in methanol for 15 seconds and moved to cold towbin
buffer for 5 minutes. Gel and membrane were assembled with one filter paper on either
end and transferred for 3 hours at a constant 300 mA power. After transfer, membranes
were rinsed in ddH2O three times, and primary antibodies were added as listed in
appendix B in fresh 5% milk blocking buffer, and rocked overnight at 4°C. Membrane
was washed in TTBS buffer (20mM Tris, 500 mM NaCl, 0.05% tween-20) three times
before secondary antibodies (Cy2 or Cy5) were added at 1:1000 in blocking buffer and
rocked for 45 minutes at room temperature. After washing 3 times in TTBS, fluorescence
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was detected using the BioRad Molecular Imaging FX, and analyzed with Quantity One
software.

Lipofectamine Transfection
Cells were plated 24 hrs before transfection. One tube was prepared to contain
optimem and lipofectamine. Optimem and plasmid DNA were added to a separate tube.
Each tube was allowed to sit at room temperature for five minutes. The lipofectamine
was added to plasmid DNA in Optimem and allowed to sit at RT for twenty minutes.
After removing media and washing with optimem, 826 ng of DNA and 1 µl
lipofectamine were added per well. Media was added to transfected cells four hours posttransfection, 1.5 ml of media/dish, 1 ml of media/well. Plates were imaged 18-48 hours
post transfection. Cells were visualized with a Zeiss AxioVert S100 TV, with a 40x oil
objective lens; images were captured using a CCD camera.

Intracellular Ca2+ Imaging
2.5–5 x105 cells were added to ECL coated 35mm dishes, and incubated at 37°C
for 48 hours. Media was removed from dishes, and 500 µl of resting buffer containing
0.05 µM Fura2-AM was added per dish and incubated for 30 minutes at room temp
protected from light. Buffer containing fura was removed, and washed with 8 mM
glucose in phosphate buffered saline. Cells were visualized with a Zeiss AxioVert S100
TV, with a 40x oil objective lens; images were captured using a CCD camera. Timelapse
images were acquired and analyzed using Slidebook software. Exposure times of 340 nm
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and 380nm of light varied between 25 ms and 80 ms. One image was taken every two
seconds and binned at 4x4. Perfusion bath changes were performed during imaging using
a gravity flow system, where flow ranged from 0.5ml per minute to 1 ml per minute.
External Solutions contained indicated amounts of glucose, sodium chloride, and
potassium. Normal, resting conditions contain 8 mM glucose, 140mM NaCl, and 2 mM
K+. Hypoglycemic conditions contain 2 mM glucose, 140mM NaCl, and 2 mM K+. High
potassium conditions contained 8 mM glucose, 140mM NaCl, and 60 mM K+. These
solutions contained 1mM MgCl2, 10mM HEPES, 5mM CaCl2 , and pH was adjusted to
7.2 using 1N NaOH. Experiments were always ended with High K buffer (60mM) to
assure proper cell Ca2+ response.
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Results
Quantitative analysis of CaMKII gene expression
Most studies of CaMKII genes have been performed in neurons and
cardiomyocytes; little is known regarding CaMKII function related to alpha cell
excitability, calcium dynamics, and glucagon secretion in the pancreas. The intracellular
signaling pathways leading to glucagon secretion from alpha cells in response to low
glucose have yet to be defined. Based on the calcium-dependent properties of these
kinases, and their involvement in excitability and signaling in neurons, we hypothesized a
similar role for CaMKII in regulating intracellular signaling during the hypoglycemic
response of pancreatic alpha cells. Detectable gene transcripts were identified for each
CaMKII gene in the αTC1-6 cell line, ßmin6	
  cell	
  line,	
  and	
  primary	
  islet	
  prepared	
  
cDNA. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to
determine if α-cells express any detectable levels of each of the four CaMKII genes.
RNA was isolated from αTC1-6, ßmin6, and islet cell lysates, and cDNA was
synthesized. Technical triplicates (n=1) were averaged from qRT-PCR and results were
normalized to GAPDH. Figure 5A shows average expression levels of all four CaMKII
genes in αTC1-6, ßmin6, and islet cells.
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Figure 5: qRT-PCR analysis of CaMKII expression.	
  (A)Relative expression of
CaMKII genes in αTC1-6 cells normalized to GAPDH. All four genes were detected by
qRT-PCR analysis. (B) Relative expression of CaMKII genes in	
  ßmin6	
  cells	
  . All four
genes were detected by qRT-PCR analysis. (C)	
  Relative expression of CaMKII genes in
primary islet cDNA.

Figure 6: Products from qRT-PCR confirming single target amplification.
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Figure	
  7:	
  qRT-PCR analysis of CaMKII expression in brain tissue.	
  D)	
  
Relative expression of CaMKII genes in an isolated mouse cortex cDNA sample. This
was used as a control for CaMKIIα primers, known to be highly expressed in the cortex.
(E) Relative expression of CaMKII in an isolated cerebellum cDNA sample. This was
used as a control for CaMKIIß	
  primers, known to be highly expressed in the cerebellum.

Figure 8: Products from qRT-PCR confirming single target amplification.
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Expression of CaMKII genes in alpha cells has not been previously characterized,
and this qRT-PCR data shows that message for all four CaMKII genes were detected in
the αTC1-6 cell line. qRT-PCR results in Figure 5B support previous findings that
CaMKIIß is expressed in the ßmin6 cell line (Dixit et al., 2013). The other three CaMKII
genes were expressed in the β-cell line as well. CaMKIIγ message showed the highest
relative expression for both alpha and beta cell lines. Figure 5C shows the relative
expression levels of all four CaMKII genes in primary mouse islet cells. Figure 6 shows
the products from the qRT-PCR reactions, confirming a single visible band at the
appropriate size for each CaMKII gene investigated. As a positive control, cDNA was
prepared from primary mouse frontal cortex and cerebellar preparations. Frontal cortex is
enriched in CaMKIIα, and the cerebellum is known to contain high levels of CaMKIIß
(Xiao et al., 2012). As expected, the cortex sample contained the highest expression of
CaMKIIα compared to the other CaMKII genes (Figure 7). The cerebellum sample in
Figure 7 contained the highest expression of CaMKIIß. This confirms that the primers
used for the qRT-PCR analysis are able to detect and amplify each CaMKII gene
expression. These results indicate that αTC1-6 cells express all four CaMKII genes, and
that CaMKIIδ and -γ are present at relatively high levels within this cell line.

Western blot analysis of CaMKII genes in αTC1-6 cells
Western blot analysis determined relative protein levels of each CaMKII gene
present in the alpha cell line (Figure 9). Mouse brain lysates were used as positive
controls for all four CaMKII genes. Similar to the results from qRT-PCR, the CaMKII
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delta and gamma proteins were the most abundant relative to their controls in alpha cell
lysates. Both CaMKIIß and CaMKIIα were not detected by western blot in the αTC1-6
cell lysate, if there, the protein levels must be extremely low.
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Figure 9: Western blot analysis of CaMKII protein levels in αTC1-6 cells the
positive control used was a mouse brain lysate (A) CaMKIIα (used at 1:1000) is
expected to be ~50kDa. Protein was detected in the cerebrum lysate, but not in the αTC16 lysate (B) CaMKIIß	
  (used	
  at	
  1	
  ug/mL)	
  is	
  expected	
  to	
  be	
  ~60	
  kDa	
  and	
  was	
  detected	
  
in	
  the	
  control	
  but	
  not	
  in	
  the	
  αTC1-‐6	
  lysate	
  (C)	
  CaMKIIδ (used at 1 ug/mL) is expected
to be ~56 kDa and protein was detected in both the control and the αTC1-6 lysate (D)
CaMKIIγ	
  	
  (used	
  at	
  1:500)	
  is	
  expected	
  to	
  be	
  ~56 kDa and protein was detected
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αTC1-6 cell Immunofluorescence
Immunofluorescence was used to observe CaMKII proteins in αTC1-6 cells
(Figures 10-12). Image analysis shows that punctate staining for CaMKIIα in the alpha
cell line is detected only in a subset of cells, where not all cells express the same levels of
CaMKIIα (Figure 10). CaMKIIβ was detected and is evenly stained among αTC1-6 cells.
The staining pattern of CaMKIIδ is punctate within this cell line. The CaMKIIγ staining
is consistent and relatively strong in αTC1-6 cells. Immunofluorescence revealed that all
four CaMKII proteins were detectable in the αTC1-6 cell line.
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Figure 10: αTC1-6 cells express CaMKIIα. CaMKIIα (red). Nuclei are visualized
with DAPI (blue).
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Figure 11: αTC1-6 cells express CaMKIIß. CaMKIIß (red). Nuclei are visualized with
DAPI (blue).
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Figure 12: αTC1-6 cells express CaMKIIδ. CaMKIIδ (red). Nuclei are visualized with
DAPI (blue).
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Figure 13: αTC1-6 cells express CaMKIIγ. CaMKIIγ (red). Nuclei are visualized with
DAPI (blue).
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In summary, CaMKII gene expression in the αTC1-6 cell line was assayed using
three different techniques, and results correlate in terms of relative detected levels of each
gene. From this data I can confirm that the αTC1-6 cell line contains all four CaMKII
genes. Localization and expression levels of each CaMKII gene differ in this cell line,
possibly pointing to individual functions for each gene. Importantly, cell lines can have
very different properties compared to primary cultures, and the presence of CaMKII in
vivo needed to be identified.

Expression of CaMKII genes in dispersed islet cells
CaMKII proteins were detected in primary mouse islet cells by
immunofluorescence. Each cell was triple stained for glucagon, insulin, and CaMKII.
Figure 12 shows the CaMKII alpha staining in a glucagon positive α-cell (14A) and an
insulin positive ß-cell (14B). Both cell types stain positive for CaMKIIα. In contrast to
the cell line data, the CaMKIIα staining pattern in primary alpha cells was not found to
be heterogeneous in expression. CaMKIIß expression was also detected in primary mouse
α- and ß-cells (Figure 15).
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Figure 14: CaMKIIα expression in primary α- and ß-cells.	
  Primary cultured alpha
cells (blue) and beta cells (red) CaMKIIa (green).
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Figure 15: CaMKIIß	
  expression in primary α- and ß-cells. Primary cultured alpha
cells (blue), CaMKIIß (green), and beta cells (red).	
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CaMKIIß was detected in both cell types, with staining mostly appearing in the
cytoplasm of each cell type. The staining pattern of CaMKIIß expression in alpha cells
appears to be greater compared to beta cells, which could be representative of a
difference in function between the two cell types. Dissociated islet cells were also imaged
to examine CaMKIIδ expression in primary alpha and beta cells (Figure 16). CaMKIIδ
was detected in both pancreatic α- and ß-cell types and appears to be mostly cytosolic.
Lastly, immunofluorescence was completed on dissociated primary islet cells to identify
CaMKIIγ staining patterns in both cell types (Figure 17). CaMKIIγ is strongly expressed
in the α- and ß-cells and staining patterns appear to be similar between the two cell types.
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Figure 16: CaMKIIδ expression in primary α- and ß-cells. Primary cultured alpha
cells (blue), CaMKIIδ (green), and beta cells (red).
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Figure 17: CaMKIIγ expression in primary α- and ß-cells.	
  Primary cultured alpha
cells (blue), beta cells (red), and CaMKIIγ (green).
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Expression of CaMKII genes in intact islet cell and tissue
Dispersion of intact islets can alter the function of each cell within the islets;
therefore, it is important to analyze CaMKII expression in an intact islet. Figure 18 shows
the presence of CaMKIIα in intact mouse pancreatic islets co-stained for glucagon and
insulin. Observing how the kinase expression appears in an intact islet may provide
insight to its function within the paracrine system of the islet. Similar to dispersed islet
stains, the CaMKIIα staining has a clear punctate pattern in alpha cells. Staining also
revealed that CaMKIIα is consistently found in beta cells. Figure 18A shows that within
an intact islet CaMKIIα is found in glucagon-containing alpha cells as well as insulincontaining beta cells. The overlay image shows the composition and number of cells
imaged in the islet by visualizing stained nuclei. Cultured islets were also fixed and
stained for CaMKIIδ and glucagon. The immunostain in Figure 19 shows this CaMKII
protein is present in both alpha and non-alpha cells within the islet. The staining pattern
shows an almost string-like appearance woven throughout the exterior of the islet. Figure
20 shows the CaMKIIγ staining that revealed that CaMKIIγ is found both in alpha and
beta cells within the islet. Intact islet stains was also completed on paraffin-embedded
pancreas sections for CaMKIIβ, shown in Figures 21 and 22. Islets were identified and
stained with glucagon, DAPI and CaMKIIβ, showing expression of the kinase in both
alpha and non-alpha cells within the mouse pancreas.
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Figure 18: Primary intact islet immunofluorescence showing CaMKIIα in the
murine islet. (A) CaMKIIα (green), followed by glucagon (red), overlay including a
DAPI nuclear stain (blue). (B) CaMKIIα (green), insulin (red), overlay including a DAPI
nuclear stain (blue)
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Figure 19: Immunofluorescence showing CaMKIIδ expression in an intact
murine islet. Primary cultured cells, showing CaMKIIδ (red) and glucagon (green)
Cellular nuclei were stained with DAPI (blue).
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Figure 20: Primary islet staining showing CaMKIIγ in alpha and beta cells. (A)
glucagon (green) CaMKIIγ (red), and the overlay showing cellular nuclei stained with
DAPI (blue). (B) insulin (green) CaMKIIγ (red), and the overlay showing cellular nuclei
stained with DAPI (blue).
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Figure 21: Paraffin embedded islet section showing CaMKIIβ and glucagon
containing alpha cells within the islet. CaMKIIβ (red) glucagon (green). Cellular nuclei
stained with DAPI (blue).

Figure 22: Paraffin embedded intact muring islets stained for both CaMKIIβ and
glucagon. This image shows a section of two islets side by side and the staining pattern
of CaMKIIβ (red), gucagon (green), and DAPI (blue) within them.
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Inhibition of CaMKII and Ca2+ dynamics
CaMKII has been characterized as an important mediator in signal transduction
and cellular function in neurons (Xiao et al., 2012, Hudman et al., 2002). Because
CaMKII has been heavily studied, reagents are readily available to alter CaMKII
function. KN-93 was first identified as a potent cell permeable inhibitor of CaMKII
specific inhibitor (Sumi et al., 1991). It has been used extensively to assess function of
CaMKII in neurons (Gao et al., 2006). In this study, KN-93 was used as a CaMKII
inhibitor to assess changes in calcium dynamics of alpha cells in response to various
conditions. αTC1-6 cells were loaded with 0.005µg/mL Fura-2AM and changes in
cytosolic calcium were measured in response to the CaMKII inhibitor, KN-93, or its
inactive structural analog KN-92. As illustrated in Figure 23, KN-93 was used to assess
changes in calcium dynamics in response to increased external potassium. αTC1-6 cells
were loaded with 0.005µg/mL of the calcium indicator Fura-2AM, and changes in
cytosolic calcium were measured in the presence or absence of KN-93 in response to high
external potassium concentrations.
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Figure 23: Calcium imaging of the αTC1-6 high potassium response in presence of
KN-93, a CaMKII inhibitor. (A) This is a figure showing the typical calcium response
to high levels (60mM) of external potassium. (B) The αTC1-6 response in the presence
of 5	
  µM KN-93 in both resting (2mM) potassium, and a change to 60mM K+ conditions.
(C) The αTC1-6 response in the presence of 5	
  µM KN-92 in both resting (2mM K+) and
change to raised 60mM K+ conditions. (D) This figure shows the response to changes
from resting (2mM) potassium to high (60mM) external potassium, when all L-type
calcium channels are blocked.
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KN-93 decreased the ability of alpha cells to respond to a strong depolarization caused by
the high external levels of potassium. Instead of the large and fast influx of calcium seen
in the controls, cells treated with KN-93 only showed a slow and gradual increase in
internal calcium in response to high external potassium levels. KN-92 was used under the
same conditions, and the cells response to high potassium levels was similar to control
cells, showing a strong peak amplitude response. To further investigate the CaMKIIindependent effects of the drugs, we used nifedipine, an L-type calcium channel blocker.
In the presence of this drug, the alpha cells maintained a normal response to increased
potassium levels.
Another approach to investigating ion channel functionality and activity is to
observe single cell ion currents using the patch-clamp technique. A collaborator on this
project, Dr. Nancy Lorenzon (University of Denver), performed electrophysiology to
view the calcium current responses in the presence of KN-93 as well as the structural
analog, KN-92 in individual alpha cells (Figure 24).
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Figure 24: αTC1-6 response of voltage gated calcium currents to CaMKII
inhibition. (A)The calcium current of a patched alpha cell in response to 5µM KN-93
compared to a non-treat control. (B)The calcium current of a patch alpha cell in response
to 5µM KN-92, the structural analog of KN-93 compared to a non-treated control cell.
(data produced by Dr. Nancy Lorenzon)
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The response to this inhibitor in a single, patched, cell showed on average a 33%
decrease (n=5) in calcium current amplitude in response to CaMKII inhibition compared
to the structural analog, KN-92, which showed on average only a 4% decrease in
amplitude (n=4). This technique, however, does not identify which calcium channels are
responsible for this decreased amplitude because alpha cells contain more than just one
type of calcium channel. The mechanism of CaMKII inhibition on the hypoglycemic
response from this result is inconclusive, but suggests a possible role for CaMKII and
calcium dynamics within alpha cells.
To further investigate the role of CaMKII in alpha cell intracellular calcium
homeostasis, the response to CaMKII inhibition in hypoglycemic conditions was
measured by Fura2 calcium imaging. Figure 25 indicates a visible decrease in the internal
calcium levels detected in alpha cells treated with the CaMKII inhibitor (KN-93) in
response to low glucose conditions compared to the control conditions. The structural
analog (KN-92) also caused a similar decrease in the amount of internal calcium within
alpha cells in response to a drop in external glucose conditions.
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Figure 25: Calcium imaging of the typical αTC1-6 response to hypoglycemic
conditions. (A) Non-treated alpha cell normal response to a change in solution from
resting (8mM) glucose conditions, to hypoglycemic (2mM) glucose conditions. (B) This
figure is showing the αTC1-6 response in the presence of 5	
  µM KN-93 in both resting
(8mM) glucose and hypoglycemic (2mM) glucose conditions. (C) This figure is showing
the αTC1-6 response to 5	
  µM KN-92 in both resting (8mM) glucose conditions, followed
by a switch to hypoglycemic (2mM) glucose conditions.
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Discussion
αTC1-6 Cell Line CaMKII Expression
The primary purpose of this study was to investigate the presence of CaMKII in
α-cells. This information was previously unknown in the field, and my study
conclusively shows that CaMKII genes are expressed in αTC1-6, min-6, and primary
mouse islet cells. Once identified, predicted functions were tested to explore if CaMKII
has a role in α-cell signaling regulation. The products from the qRT-PCR reactions
confirm a single visible band at the appropriate size of each CaMKII gene investigated in
all cells used. These findings from qRT-PCR shows that all four CaMKII genes are
expressed in αTC1-6 cells, min-6 cells, as well as in primary islet cells. Protein levels of
all four CaMKII genes in αTC1-6 cells were assessed by Western blot techniques.
CaMKII alpha was not detected using this assay. The staining revealed that only a subset
of cells contained CaMKIIα in this cell line, and the qRT-PCR showed detectable, but
relatively low message. However, message does not always correlate with protein levels,
so this result was not unexpected.

Primary α-Cell CaMKII Expression
Results from this study show that primary mouse alpha and beta cells contain all
four CaMKII proteins, and this was illustrated through immunofluorescence results.
Some important differences between the primary cells and the cell line Interesting results
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were seen in the immunofluorescence data from viewing the staining pattern of CaMKIIα
in primary alpha cells. In the cell line, CaMKIIα staining is heterogeneic, but in the
primary alpha cells CaMKIIα was found to be consistently expressed in all identified
alpha cells. Immunofluorescence from both dispersed and intact islet showed that both
primary alpha and beta cells contain CaMKIIβ. The apparent polarized staining pattern of
CaMKIIδ seen in the alpha cell line was not observed in the primary alpha cell cultures.
This could be due to changes in physical characteristics of the alpha cells in a cultured
cell line, and not typical primary alpha cell behavior, although further studies would need
to be completed to investigate this further. The CaMKII gamma staining patterns were
very similar between dispersed and intact islet alpha cells, possibly pointing towards a
vital function for this CaMKII gene in homeostasis and overall cell function.
The hypothesis that CaMKII genes are involved in maintaining calcium
homeostasis and regulation in alpha cells has yet to be elucidated. Because these CaMKII
proteins have been shown to perform many functions in many different tissues, it is
possible that they are implicated in other cellular functions aside from glucagon secretion
due to a change in glucose levels. These proteins could be involved in any number of
intracellular pathways, such as vesicle trafficking, release from internal calcium stores, or
exocytotic machinery, all which could alter glucagon secretion via other pathways. A
future step for this study is to label primary alpha cells from dispersed islet preparations
in order to observe the calcium response to external stimuli. Additional studies need to be
performed in order to investigate a possible connection between internal calcium levels
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and activation of CAMKII in primary cell cultures, before a role for CaMKII in alpha cell
signaling is clear.
In addition to labeling alpha cells, functional studies on intact islets would be
more relevant in investigating paracrine functions within the islet. Recent studies on
primary islets indicate that dissociating islet cells alters functionality of the cell types
within it (Marchand et al., 2010). Because dissociating these cells may disguise or alter
important cellular functions, experiments should be performed on intact islet cells as
well. In order to perform additional functional studies, culturing conditions need to be
improved, and functionality needs to be assessed. Once culturing conditions are able to
consistently identify alpha cells and maintain proper ion channel function, more detailed
studies can be performed to investigate the importance of each CaMKII protein on islet
cell functionality and signaling in response to low glucose conditions.

Altered Ca2+ Dynamics and CaMKII Inhibition
A CaMKII inhibitor, KN-93 was used to study what role, if any CaMKII has in
calcium dynamics within alpha cells. In control conditions, high external potassium
reverses the concentration gradient within the cell, causing potassium ions to enter the
cell. This results in a strong depolarization and opening of all voltage dependent channels
within the cell. This is visualized by a strong peak amplitude response to internal calcium
within the cells, seen in Figure 23A. Calcium imaging studies showed there was an
altered internal calcium response to high external potassium levels when CaMKII activity
was inhibited, Figure 23B. The inactive structural analog used showed a similar peak
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amplitude response as non-drug treated control conditions (Figure 23C), suggesting the
results seen were due to the inhibition of CaMKII activity. It is possible that inhibiting
CaMKII in the alpha cells causes altered potassium channel function, or function of
another downstream ion channel important in Ca2+ influx, causing the detected decrease
in internal Ca2+. Alpha cells have several important ion channels, which can influence
calcium dynamics. These results could be due to inhibition of K+ permeability, preventing
initial cell depolarization. Another possibility is that L- or N-type calcium channels are
being blocked or inactivated by CaMKII inhibition, which would also result in decreased
internal calcium levels. Nifedipine was used to test the effect blocked L-type calcium
channels would have on the high potassium response, seen in Figure 23D. When the Ltype calcium channels were blocked, however, the results were similar to control
conditions, where increased internal calcium was observed. This indicates that CaMKII
inhibition is not affecting L-type calcium channels under these conditions, and is likely
blocking N-type channel activity.
An additional technique of observing and measuring calcium dynamics within
cells was used to further investigate the role of CaMKII in alpha cell signaling and
secretion. Alpha whole-cell current amplitudes were measured in response to KN-93 in
hypoglycemic conditions using patch clamp techniques. The results showed that the KN92 analog was responsible for only a slight decrease in whole-cell calcium current
amplitude (4%), while KN-93 had a larger effect (33%) decrease on calcium current
amplitude within the cell. These results further implicate CaMKII in regulation of
calcium dynamics within alpha cells. This assay showed that CaMKII is potentially
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involved with the calcium dynamics involved in the hypoglycemic response, and we
believe this is due to the blocking of N-type calcium channels. This technique, however,
does not definitively identify which calcium channels are responsible for this decreased
amplitude because alpha cells contain more than just one type of calcium channel.
To explore this response further, additional Fura2 calcium imaging experiments
were performed to begin investigating a more specific role for CaMKII in response to
hypoglycemic conditions. Previous studies in the Angleson lab have reported that the
hypoglycemic response is due to both L- and N-type calcium channel activity. When one
of the two channels is blocked, the hypoglycemic response is decreased compared to
normal non-treated conditions. When both L-and N-type calcium channels are blocked,
there is no immediate calcium response to hypoglycemic conditions (L. Liang thesis,
2009). This previous study also showed that there is a delayed acute hypoglycemic
response caused by calcium induced calcium release (CICR), which is dependent on both
L- and N-type calcium channels, leading to prolonged store release. Results from the KN93 assays in this study showed that both the active and inactive inhibitor caused a
decrease in internal calcium compared to control hypoglycemic conditions, indicating
that the drugs’ CaMKII-independent effects were partially responsible for inhibiting the
normal hypoglycemic response, while masking the direct effect of CaMKII inhibition on
internal calcium. Although KN inhibitors have relatively high CaMKII selectivity, they
cannot distinguish between CaMKII and CaMKIV, and have been shown to affect some
voltage-gated Ca2+ and K+ channels (Coultrap et al., 2011).
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The KN-93 studies on the high potassium internal calcium response indicated that
CaMKII inhibition is likely not targeting L-type calcium channels. It is possible that the
indirect effects of this inhibitor used in these studies potentially masked a distinct, visible
internal calcium changes due to CaMKII inhibition of N-type calcium channels within
alpha cells in response to low glucose conditions. It is also possible that CaMKII
inhibition could affect the prolonged calcium release from internal stores in response to
hypoglycemic conditions. Because of the documented non-specific effects of the KN
inhibitors, a different CaMKII inhibitor should be used to further characterize CaMKII
function in excitability and Ca2+ dynamics within the alpha cell.
Results from this study implicate CaMKII as a possible regulator of alpha cell
signaling. In Type 1 diabetes, beta cells are not present, and glucose homeostasis relies
solely on the alpha cells within the islet to maintain glucose homeostasis. Results from
KN-93 assays in this study implicate CaMKII as a possible mediator of calcium
dynamics leading to glucagon secretion. Because calcium influx is required for
exocytosis in these cells, the preliminary studies performed in this thesis implicate
CaMKII as a possible initiator and/or suppressor of glucagon secretion in response to an
increase or decrease in internal calcium. It is possible that CaMKII could be targeted in
patients with Type 1 diabetes to enhance or suppress glucagon secretion to help maintain
glucose homeostasis.
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Future Directions
Peptide Inhibition of CaMKII
The CaMKII inhibitor used in this work is known as a “messy inhibitor”. Previous
studies indicate the KN-93 inhibitor not only blocks CaMKII activity, but also reduces
currents from L-type calcium channels in a CaMKII- independent matter (Gao et al.,
2006). The alpha cell line and primary mouse alpha cells used in these studies contain Ltype calcium channels, likely affected by treatment with this drug. Because of this, the
results from the KN-93 Ca2+ imaging studies are inconclusive. Ulrich Bayer (University
of Colorado Denver) and colleagues report a more specific natural inhibitor, CN-21 (Vest
et al., 2007). Not only is this a “cleaner inhibitor” it also blocks all CaMKII protein
activity. This inhibitor completely blocks Ca2+-stimulated and autonomous substrate
phosphorylation by CaMKII and autophosphorylation at T305. Use of this inhibitor might
answer the broader question regarding CaMKII involvement in Ca2+ dynamics and
glucagon secretion within the αTC1-6 cell line.

siRNA inhibition of CaMKII beta, delta, and gamma
Additional calcium imaging studies need to be performed in order to determine a
role for individual CaMKII proteins. One approach is to knock down expression of
individually CaMKII genes and visualize calcium dynamics within the cell. A CaMKIIα
siRNA construct was transfected into αTC1-6 cells, efficiency was measured, and results
are discussed in Appendix A. CaMKIIα expression in the αTC1-6 cell line is
heterogeneic, and therefore is not the best CaMKII gene to use in studying the function of
60

CaMKII in alpha cells. siRNA constructs for CaMKII beta, delta, and gamma would be
useful tools to study the role of each CaMKII gene in alpha cell signaling because these
genes are more consistently found within αTC1-6 cells. The constructs could be used to
measure changes in internal calcium levels in response to hypoglycemic conditions when
a single CaMKII gene is knocked out of αTC1-6 cells. Knockdown efficiency would be
measured using Western blot techniques and immunofluorescence. These assays used
together would confirm appropriate knockdown of expression and produce viable data for
interpretation. Pilot studies were conducted using copGFP Control Lentiviral Particles
(Santa Cruz). Three days post-infection media containing virus was removed and media
containing puromycin (50 mg/mL) was added for selectivity, and within 24 hours over
95% of the αTC1-6 cells were GFP positive. Using these lentiviral constructs for the
different CaMKII genes would assist in identifying a mechanism of action for CaMKII in
glucagon secreting alpha cells within the pancreatic islet.

Altered CaMKII and glucagon secretion
ELISA assays are useful to answer questions about direct connections between
treatment with drug and secretion. It would be interesting to know if treatment with the
CaMKII inhibitor decreases glucagon secretion in response to hypoglycemic conditions.
As mentioned in the introduction, an influx in [Ca2+]i is required for glucagon secretion.
As discussed in the results section, it appears that inhibiting CaMKII also decreased the
amount of [Ca2+]i in response to hypoglycemic conditions. If Ca2+ dynamics are altered,
the Ca2+-dependent secretion should be altered as well. Results from an ELISA assay
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would strengthen these findings. This assay could also be used to study the effect of the
siRNA CaMKII constructs on glucagon secretion, as well as to help to suggest possible
mechanisms of action of each CaMKII gene in the alpha cells within the pancreatic islet.

Altered CaMKII alpha Activity
Plasmid constructs for expression of WT, constitutively active (T286D,
phosphomimetic), and kinase-dead (K42M) CaMKIIα were supplied as a generous gift
from Ulrich Bayer (University of Colorado Denver). The three constructs were made
using the same vector plasmid, pEGFP-C1 (Clontech). Transfection efficiencies for each
plasmid in the αTC1-6 cell line were: WT CaMKIIα (31%), CaMKIIα-T286D (28%), and
CaMKII-K42M (21%) efficiency. Pilot transfections were performed to investigate the
hypoglycemic response when CaMKIIα function was altered. A calcium dye indicator
other than Fura-2, such as Fura-red (Invitrogen), needs to be used in order to ensure the
GFP-positive transfected cells are not interfering with internal calcium measurements
within the cells. This assay will be useful in determining the requirement of CaMKIIα
function in regulation of calcium signaling and glucagon release from pancreatic alpha
cells.
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Mouse model to address paracrine signaling of CaMKII
In vivo studies can answer many questions that in vitro studies cannot. The best
way to address the paracrine signaling aspect of this project would be to see the direct
effects of CaMKII knockdown in vivo within an intact islet on glucose secretion and
regulation. CaMKIIα is commonly studied in the forebrain, and a floxed mouse is readily
available from JAX laboratory. Crossing this line to a B-actin:Cre mouse would knock
CaMKIIα out of all cell types where it is normally present. Although this would be useful
in studying CaMKII function in intact islets, this knockdown of CaMKIIα could cause
additional complications in other tissues. A cre-specific mouse makes it possible to study
a direct effect of CaMKIIα on glucagon secretion as well as glucose homeostasis. Blood
samples from an alpha cell specific CaMKIIα knockout mouse (proglucagon:Cre;
CaMKIIαfx/fx) could be used to study the hypoglycemic response as well as recovery from
an insulin tolerance test. If recovery or maintenance of glucose homeostasis is affected, it
would implicate CaMKIIα as a possible mediator of glucose regulation within the
pancreatic islet.
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Appendix A: siRNA knockdown of CaMKII alpha
To further investigate CaMKII function in intracellular alpha cell signaling,
CaMKII alpha was knocked down using an siRNA expression system. A pSilencer 2.1U6 puro (Invitrogen) containing an siRNA designed against CaMKIIα was supplied as a
generous gift from Ulrich Bayer (University of Colorado – Anschutz Medical Campus).
The siRNA was co-transfected along with an E-YFP expression vector into αTC1-6 cells
and knock down efficiency was measured (Figure 24). Successfully transfected cells,
indicated by EGFP expression, show knockdown of CaMKIIα expression within the
cells. Appendix C shows CaMKIIα expression in both GFP positive and negative alpha
cells. This figure also shows a quantification of fluorescent intensity of CaMKIIα
expression between GFP positive and negative cells. This construct was able to decrease
average fluorescence levels of CaMKIIα expression in transfected cells. Due to the
heterogeneity of CaMKIIα expression in the αTC1-6 cell line, the effects of CaMKIIα
knockdown on Ca2+ dynamics were inconclusive. To simplify the knockdown procedure
of CaMKIIα, the U6:CaMKIIα siRNA cassette (EcoRI-HinDIII) was sublconed into
pSuper-tdTomato/neo (EcoRI-HinDIII) (modified from OligoEngine pSuper-GFP/neo), a
plasmid that co-expresses both the siRNA and a fluorescent reporter, allowing accurate
identification of knockdown cells using a single expression vector. With proper controls,
further calcium imaging studies with this construct can be used to study the effect, if any
CaMKIIα has on calcium dynamics within alpha cells in response to low glucose
conditions.
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Appendix A: αTC1-6 cells treated with shRNA CaMKIIα. (A) an image of CaMKIIα
expression and EGFP expression in αTC1-6 cells. (A’) CaMKIIα immunostain showing
the GFP positive cell has little to no CaMKIIα detection (B) quantification of CaMKIIα
fluorescence intensity for GFP positive and negative αTC1-6 cells.
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Appendix B: Table of Antibodies

Antibody

Company/id

Concentration species

CaMKIIα

05-535 (Millipore)

ICC: 1/100

Mouse

WB: 2µg/mL
CBalpha2
CaMKIIβ

University of
Colorado (U. Bayer)
Ab34703 (AbCam)

ICC: 1:100

Mouse

ICC: 1:300

Rabbit

WB:1µg/mL

CaMKIIδ

Ab105502 (AbCam)

ICC: 5µg/mL

Rabbit

WB: 1µg/mL
CaMKIIγ

Ab37999 (AbCam)

ICC: 1:100

Rabbit

WB: 1/500
Glucagon

2013-07 (DAKO)

ICC: 1:100

Rabbit

Insulin

2013-08 (DAKO)

ICC1:100

Guinea
Pig

Glucagon

Sigma G2654

ICC1:500
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Mouse

Appendix C: Table of Abbreviations

Abbreviations
CaMKII
RyR2
IP3

Ca2+/Camodulin Kinase II
Ryanodine receptor
inositol 1,4,5-triphosphate

VGCC

Voltage gated calcium channel

iGLU

ionitropic glutamate receptor

AMPA

GLU

a-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid receptor
N-methyl-D-aspartate ionotropic
gluatmate receptor
glucose

CICR

Calcium induced calcium release

cAMP

Cyclic Adenosine monophosphate

GABA

Gamma-Aminobutyric Acid

GAD

Glutamate Decarbooxylase

NMDA

LDCV

Large dense core vesciles

PSD

Post synaptic density

LTP

Long term potentiation

SR

Sarcoplasmic reticulum
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